心力衰竭患者利尿剂抵抗的机制及治疗进展
摘要
程中常见的一大临床难题，常常导致住院期间患者的病情恶化，同时导致患者的住院时间延长、病死率和再住院率增加。
利尿剂抵抗是当前重要的研究内容，本文将从利尿剂抵抗的机制、治疗方法及进展等方面进行综述，为临床利尿剂的治疗
提供帮助。
关键词
全文:
PDF参考
[1]WANG H. Age-specific and sex-specific mortality in 187
countries, 1970-2010: a systematic analysis for the Global Burden
of Disease Study 2010 [J]. Lancet, 2012, 380(9859):p. 2071-94.
[2] 王宙 . 慢性心力衰竭的流行病学研究现状及其防治研
究进展 [J]. 中国循证心血管医学杂志 , 2019, 11(08):p. 1022-
1024.
[3] 王华 . 中国住院心力衰竭患者流行病学及治疗现状
[J]. 中华心血管病杂志 , 2019, 47(11).
[4]GUPTA R, TESTANI J, COLLINS S. Diuretic Resistance
in Heart Failure [J]. Curr Heart Fail Rep, 2019, 16(2):p. 57-66.
[5]RAHMAN R. Diuretic Resistance in Heart Failure [J].
Cardiology in Review, 2021, 29(2):p. 73-81.
[6] 马妍 . 慢性心力衰竭利尿剂抵抗的发病机制与治疗
进展 [J]. 世界中医药 :p. 1-10.
[7]KNAUF H, MUTSCHLER E. Sequential nephron blockade
breaks resistance to diuretics in edematous states [J]. J Cardiovasc
Pharmacol, 1997, 29(3):p. 367-72.
[8]BENJAMIN E J. Heart Disease and Stroke Statistics-2019
Update A Report From the American Heart Association [J].
Circulation, 2019, 139(10):p. E56-E528.
[9]BIEGUS J. Spot urine sodium in acute heart failure:
differences in prognostic value on admission and discharge [J].
ESC Heart Fail, 2021, 8(4):p. 2597-602.
[10]TESTANI J M. Rapid and Highly Accurate Prediction of
Poor Loop Diuretic Natriuretic Response in Patients With Heart
Failure [J]. Circ Heart Fail, 2016, 9(1):p. e002370.
[11]TESTANI J M. Loop diuretic efficiency: a metric of
diuretic responsiveness with prognostic importance in acute
decompensated heart failure [J]. Circ Heart Fail, 2014, 7(2):p.
261-70.
[12]DE BRUYNE L K M. Mechanisms and management of
diuretic resistance in congestive heart failure [J]. Postgraduate
Medical Journal, 2003, 79(931):p. 268-71.
[13]WILCOX C S, TESTANI J M, PITT B. Pathophysiology
of Diuretic Resistance and Its Implications for the Management of
Chronic Heart Failure [J]. Hypertension, 2020, 76(4):p. 1045-54.
[14]COSTANZO M R. Hypertonic Saline: The Genesis of
the Exodus of Fluid in Heart Failure? ∗ [J]. JACC: Heart Failure,
2020, 8(3):p. 209-11.
[15]KHAN M S, JONES D W, BUTLER J. Salt, No Salt, or
Less Salt for Patients With Heart Failure? [J]. American Journal of
Medicine, 2020, 133(1):p. 32-8.
[16]BRATER D C. Absorption and disposition of furosemide
in congestive heart failure [J]. Kidney Int, 1982, 22(2):p. 171-6.
[17]GUAZZI M. Pathophysiology of cardiorenal syndrome
in decompensated heart failure: role of lung-right heart-kidney
interaction [J]. Int J Cardiol, 2013, 169(6):p. 379-84.
[18]ROSE H J, O’MALLEY K, PRUITT A W. Depression
of renal clearance of furosemide in man by azotemia [J]. Clin
Pharmacol Ther, 1977, 21(2):p. 141-6.
[19]GRODIN J L. Clinical Implications of Serum Albumin
Levels in Acute Heart Failure: Insights From DOSE-AHF and
ROSE-AHF [J]. J Card Fail, 2016, 22(11):p. 884-90.
[20]CHAROKOPOS A. Serum and Urine Albumin and
Response to Loop Diuretics in Heart Failure [J]. Clin J Am Soc
Nephrol, 2019, 14(5):p. 712-8.
[21]MULLENS W. Renal sodium avidity in heart failure:
from pathophysiology to treatment strategies [J]. Eur Heart J, 2017,
38(24):p. 1872-82.
[22]COX Z L, TESTANI J M. Loop diuretic resistance
complicating acute heart failure [J]. Heart Failure Reviews, 2020,
25(1):p. 133-45.
[23]HALL D. Controversies in heart failure. Are beneficial
effects of angiotensin-converting enzyme inhibitors attenuated
by aspirin in patients with heart failure? [J]. Cardiol Clin, 2001,
19(4):p. 597-603.
[24]NA K Y. Upregulation of Na+ transporter abundances in
response to chronic thiazide or loop diuretic treatment in rats [J].
Am J Physiol Renal Physiol, 2003, 284(1):p. F133-43.
[25]RAO V S. Compensatory Distal Reabsorption Drives
Diuretic Resistance in Human Heart Failure [J]. J Am Soc
Nephrol, 2017, 28(11):p. 3414-24.
[26] 王华 , 梁延春 . 中国心力衰竭诊断和治疗指南 2018
[J]. 中华心血管病杂志 , 2018, 46(10):p. 760-89.
[27]AFARI M E. Subcutaneous furosemide for the treatment
of heart failure: a state-of-the art review [J]. Heart Failure
Reviews, 2019, 24(3):p. 309-13.
[28]JENTZER J C, DEWALD T A, HERNANDEZ A F.
Combination of Loop Diuretics With Thiazide-Type Diuretics in
Heart Failure [J]. Journal of the American College of Cardiology,
2010, 56(19):p. 1527-34.
[29]BRISCO-BACIK M A. Outcomes Associated With a
Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in
Acute Decompensated Heart Failure: A Propensity Analysis [J]. J
Am Heart Assoc, 2018, 7(18):p. e009149.
[30]KONSTAM M A. Effects of oral tolvaptan in patients
hospitalized for worsening heart failure: the EVEREST Outcome
Trial [J]. Jama, 2007, 297(12):p. 1319-31.
[31] 中国心力衰竭诊断和治疗指南 2018 [J]. 中华心力衰
竭和心肌病杂志 , 2018, (04):p. 196-7-8-9-200-1-2-3-4-5-
6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-
24-25.
[32]BUTLER J. Rationale and Design of the ATHENAHF Trial: Aldosterone Targeted Neurohormonal Combined With
Natriuresis Therapy in Heart Failure [J]. JACC Heart Fail, 2016,
4(9):p. 726-35.
[33]MULLENS W. Rationale and design of the ADVOR
(Acetazolamide in Decompensated Heart Failure with Volume
Overload) trial [J]. Eur J Heart Fail, 2018, 20(11):p. 1591-600.
[34]GRIFFIN M. Sodium glucose cotransporter 2 inhibitors
as diuretic adjuvants in acute decompensated heart failure: a case
series [J]. Esc Heart Failure, 2020, 7(4):p. 1966-71.
[35]YANCY C W. 2013 ACCF/AHA guideline for the
management of heart failure: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines [J]. J Am Coll Cardiol, 2013, 62(16):p. e147-
239.
[36]SHEN X L. Safety and efficacy of ultrafiltration on
heart failure patients with reduced ejection fraction and diuretic
resistance: results from a single-center randomized controlled trial
[J]. Zhonghua xin xue guan bing za zhi, 2021, 49(4):p. 340-4.
(6 摘要 Views, 34 PDF Downloads)
Refbacks
- 当前没有refback。